2-Mercaptoethanesulfonic Acid

2-Mercaptoethanesulfonic Acid

SCHEMBL2301571

O=S(=O)([O-])CCS.O=S(=O)([O-])CCS.[Na+].[Na+]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of 2-Mercaptoethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS1 known ✓ P23219 1/20 0.45
PDE4A known ✓ P27815 1/20 0.45
KDM4E B2RXH2 1/20 1.00
MAPT P10636 1/20 1.00
ALOX15 P16050 1/20 1.00
ENPEP Q07075 2/20 0.48
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46
GMNN O75496 1/20 0.46
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
THPO P40225 1/20 0.46
HBB P68871 1/20 0.46
PMP22 Q01453 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
BBOX1 O75936 3/20 0.36
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019024784-A1 FATTY ACID CONJUGATED NANOPARTICLES AND USES THEREOF THE CHINESE UNIVERSITY OF HONG KONG (CN) 2019-02-07 WO claimed
US-20190029970-A1 FATTY ACID CONJUGATED NANOPARTICLES AND USES THEREOF THE CHINESE UNIVERSITY OF HONG KONG (CN) 2019-01-31 US claimed
CN-102015739-A Novel compounds and methods for treatment GILEAD SCIENCES INC 2011-04-13 CN claimed
WO-2007149103-A2 VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE KAISER DANIEL E (US) 2007-12-27 WO claimed
EP-4444323-A1 ANTI-VIRAL THERAPEUTIC AGENTS AND USES THEREOF Cila Therapeutic Inc. (US) 2024-10-16 EP disclosed
US-20240307333-A1 ANTI-VIRAL THERAPEUTIC AGENTS AND USES THEREOF Cila Therapeutics Inc. (US) 2024-09-19 US disclosed
WO-2023180353-A1 COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY F. HOFFMANN-LA ROCHE AG (CH) 2023-09-28 WO disclosed
CN-116529360-A Methods and compositions for stimulating γδ T cells 弗罗里达中央大学研究基金会 2023-08-01 CN disclosed
WO-2023107996-A1 ANTI-VIRAL THERAPEUTIC AGENTS AND USES THEREOF CILA THERAPEUTIC INC. (US) 2023-06-15 WO disclosed
US-10928405-B2 Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells ANALIZA, INC. (US) 2021-02-23 US disclosed
EP-3675838-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS Puretecch LYT, Inc. (US) 2020-07-08 EP disclosed
EP-3080341-B1 METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS ANALIZA INC (US) 2020-02-12 EP disclosed
CN-102015739-A Novel compounds and methods for treatment GILEAD SCIENCES INC 2011-04-13 CN disclosed
CN-101903384-A As [1H-pyrazolo [3,4-B] the pyridin-4-yl]-phenyl of protein kinase C theta inhibitors or-pyridine-2-radical derivative VERTEX PHARMA 2010-12-01 CN disclosed
CN-101801959-A Aminopyrimidines useful as kinase inhibitors VERTEX PHARMA 2010-08-11 CN disclosed
CN-101679378-A Thiazoles and pyrazoles as kinase inhibitors VERTEX PHARMA 2010-03-24 CN disclosed
CN-101679387-A Aminopyrimidines useful as kinase inhibitors VERTEX PHARMA 2010-03-24 CN disclosed
CN-101663276-A 2-aminopyridine derivatives useful as kinase inhibitors VERTEX PHARMA 2010-03-03 CN disclosed
CN-101500613-A A novel lactic acid formulation of MK-0457 useful for the treatment of cancer MERCK & CO INC (US) 2009-08-05 CN disclosed
US-20050058622-A1 Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens IMMUNEX CORPORATION 2005-03-17 US disclosed